Business
Jaguar Health to Host Investor Call April 6th at 8:30 a.m. Eastern Regarding Q4 2019 Financials & Business Updates
Company Filed its Annual Report on April 3, 2020 on Form 10-K for the Fiscal Year Ended December 31, 2019SAN FRANCISCO, CA / ACCESSWIRE / April 3, 2020 /
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Company Filed its Annual Report on April 3, 2020 on Form 10-K for the Fiscal Year Ended December 31, 2019SAN FRANCISCO, CA / ACCESSWIRE / April 3, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today announced that Company management will host a conference call on Monday, April 6, 2020 at 8:30 a.m. Eastern Time to provide updates regarding fourth-quarter 2019 financials and business updates.On April 3, 2020 the Company filed with the U.S. Securities and Exchange Commission its annual report on Form 10-K for the fiscal year ended December 31, 2019.Dial-In Instructions for Conference CallWhen: April 6, 2020 at 8:30 a.m. Eastern TimeDial-in (US Toll Free): 888-394-8218Dial-in (International): 323-701-0225Conference ID number: 7352525Live webcast on the investor relations section of Jaguar's website (click here)Replay InstructionsDial-in (US Toll Free): 844-512-2921Dial-in (International): 412-317-6671Replay Pin Number: 7352525Replay of the webcast on the investor relations section of Jaguar's website (click here)About Jaguar Health, Inc.Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.About Mytesi®Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection...